JP2022545226A5 - - Google Patents

Info

Publication number
JP2022545226A5
JP2022545226A5 JP2022510971A JP2022510971A JP2022545226A5 JP 2022545226 A5 JP2022545226 A5 JP 2022545226A5 JP 2022510971 A JP2022510971 A JP 2022510971A JP 2022510971 A JP2022510971 A JP 2022510971A JP 2022545226 A5 JP2022545226 A5 JP 2022545226A5
Authority
JP
Japan
Prior art keywords
receptor
item
neuron
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022510971A
Other languages
English (en)
Japanese (ja)
Other versions
JP7781052B2 (ja
JP2022545226A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047503 external-priority patent/WO2021035179A1/en
Publication of JP2022545226A publication Critical patent/JP2022545226A/ja
Publication of JP2022545226A5 publication Critical patent/JP2022545226A5/ja
Priority to JP2024180241A priority Critical patent/JP2025004243A/ja
Application granted granted Critical
Publication of JP7781052B2 publication Critical patent/JP7781052B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022510971A 2019-08-21 2020-08-21 神経学的疾患のための組成物および方法 Active JP7781052B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180241A JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889963P 2019-08-21 2019-08-21
US62/889,963 2019-08-21
PCT/US2020/047503 WO2021035179A1 (en) 2019-08-21 2020-08-21 Compositions and methods for neurological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180241A Division JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022545226A JP2022545226A (ja) 2022-10-26
JP2022545226A5 true JP2022545226A5 (https=) 2023-08-29
JP7781052B2 JP7781052B2 (ja) 2025-12-05

Family

ID=72356519

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022510971A Active JP7781052B2 (ja) 2019-08-21 2020-08-21 神経学的疾患のための組成物および方法
JP2024180241A Pending JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024180241A Pending JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Country Status (7)

Country Link
US (1) US20220348635A1 (https=)
EP (1) EP4017874A1 (https=)
JP (2) JP7781052B2 (https=)
CN (1) CN114746450A (https=)
AU (1) AU2020334147A1 (https=)
CA (1) CA3151920A1 (https=)
WO (1) WO2021035179A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304040B2 (en) 2016-07-07 2024-09-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
SG11202004246YA (en) 2017-11-10 2020-06-29 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
IL300816A (en) * 2020-08-21 2023-04-01 Trames Bio Inc Preparations and methods for neurological diseases
US20250009906A1 (en) * 2021-11-19 2025-01-09 President And Fellows Of Harvard College Nociceptor-specific gene regulatory elements for the treatment of pain
EP4473002A4 (en) * 2022-01-31 2026-04-08 Hughes Howard Med Inst Modified ion channels sensitive to a ligand and methods of use
KR20240161957A (ko) * 2022-02-18 2024-11-13 트라메스 바이오 인코포레이티드 리간드 개폐 이온 통로 및 사용 방법
EP4514831A1 (en) * 2022-04-27 2025-03-05 Howard Hughes Medical Institute Chemogenetic receptors and methods of making and using
WO2025117698A1 (en) * 2023-12-01 2025-06-05 Massachusetts Institute Of Technology Ribozyme-enhanced rna trans-splicing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
AU8672198A (en) 1997-07-31 1999-02-22 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
DK1009808T3 (da) 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
JP2003523320A (ja) 1999-09-29 2003-08-05 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ウイルスベクターの迅速なｐｅｇ改変方法、高められた遺伝子形質導入のための組成物、高められた物理的安定性を伴う組成物、およびそのための用途
US7358057B2 (en) 2002-05-09 2008-04-15 Memory Pharmaceuticals Corporation QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
TW200412942A (en) 2002-08-06 2004-08-01 Abbott Lab Appetite control method
EP1592710A2 (en) 2003-02-14 2005-11-09 Memory Pharmaceutical Corporation Macaque alpha-7 nicotinic acetylcholine receptor and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
WO2009042723A1 (en) 2007-09-25 2009-04-02 California Institute Of Technology Transgenic mice expressing hypersensitive nicotinic receptors
JP5511144B2 (ja) 2008-02-12 2014-06-04 学校法人福岡大学 てんかんモデル非ヒト哺乳動物
EP2344636B1 (en) 2008-10-09 2017-12-06 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US11713470B2 (en) 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders
SG11202004246YA (en) 2017-11-10 2020-06-29 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
US10538571B2 (en) 2017-11-27 2020-01-21 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases

Similar Documents

Publication Publication Date Title
JP2022545226A5 (https=)
JP7482549B2 (ja) 新規のマイクロジストロフィンおよび使用の関連する方法
JP2022141670A5 (https=)
RU2019103488A (ru) Способы и композиции для лечения нарушений и заболеваний, связанных с rdh12
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
RU2018112506A (ru) Лечение пигментного ретинита
JP2022531809A (ja) ＡＴＰａｓｅ媒介性疾患の処置のための組成物および方法
JP2023538130A5 (https=)
JP2024513949A5 (https=)
JP7289306B2 (ja) 網膜障害を治療するための組成物及び方法
JP2019524090A5 (https=)
JP2021075550A (ja) グルカゴン類似ペプチド−１受容体亢進剤を含む筋減少症治療用薬学組成物
JP2022513454A (ja) ＡＩＭＰ２－ＤＸ２およびｍｉＲ－１４２の標的核酸を含むベクター、ならびにその使用
JP2023514446A5 (https=)
JP2022512579A5 (https=)
JP2025508429A5 (https=)
JP2021534206A5 (https=)
JP2024133479A5 (https=)
EP4008789B1 (en) Bicistronic aav vector for rna interference in als
CN115475247B (zh) β2-微球蛋白或其抑制剂的制药用途
JP2022519596A (ja) Ｃｌｎ３ポリヌクレオチドのアデノ随伴ウイルス送達
JP2023551254A5 (https=)
JP2024505197A5 (https=)
JP2025508427A5 (https=)
JP2023543361A (ja) Ｎｅｕｒｏｄ１及びｄｌｘ２ベクター